KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Acquisitions (2018 - 2021)

Amneal Pharmaceuticals (AMRX) has 3 years of Acquisitions data on record, last reported at $72.7 million in Q4 2021.

  • For Q4 2021, Acquisitions changed N/A year-over-year to $72.7 million; the TTM value through Dec 2022 reached $72.7 million, down 50.38%, while the annual FY2022 figure was $84.7 million, 42.19% down from the prior year.
  • Acquisitions reached $72.7 million in Q4 2021 per AMRX's latest filing, down from $73.8 million in the prior quarter.
  • Across five years, Acquisitions topped out at $253.6 million in Q1 2020 and bottomed at -$2.6 million in Q3 2020.
  • Average Acquisitions over 3 years is $66.9 million, with a median of $38.0 million recorded in 2018.
  • The widest YoY moves for Acquisitions: up 19587.47% in 2021, down 19587.47% in 2021.
  • A 3-year view of Acquisitions shows it stood at $3.3 million in 2018, then crashed by 179.76% to -$2.6 million in 2020, then surged by 2854.36% to $72.7 million in 2021.
  • Per Business Quant database, its latest 3 readings for Acquisitions were $72.7 million in Q4 2021, $73.8 million in Q2 2021, and -$2.6 million in Q3 2020.